Dianthus Therapeutics, Inc. (DNTH)
107.75
-3.79
(-3.40%)
USD |
NASDAQ |
Aug 28, 10:10
Dianthus Therapeutics Cash from Operations (Quarterly) : -48.98M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -48.98M |
| March 31, 2026 | -28.86M |
| December 31, 2025 | -46.98M |
| September 30, 2025 | -30.56M |
| June 30, 2025 | -23.89M |
| March 31, 2025 | -27.63M |
| December 31, 2024 | -27.44M |
| September 30, 2024 | -21.27M |
| June 30, 2024 | -14.53M |
| March 31, 2024 | -14.94M |
| December 31, 2023 | -11.85M |
| September 30, 2023 | -9.992M |
| June 30, 2023 | -4.731M |
| March 31, 2023 | -10.28M |
| December 31, 2022 | -8.851M |
| September 30, 2022 | 16.38M |
| June 30, 2022 | -16.85M |
| March 31, 2022 | -19.74M |
| December 31, 2021 | -15.69M |
| Date | Value |
|---|---|
| September 30, 2021 | -14.07M |
| June 30, 2021 | -13.00M |
| March 31, 2021 | -16.77M |
| December 31, 2020 | -13.73M |
| September 30, 2020 | -14.43M |
| June 30, 2020 | -19.20M |
| March 31, 2020 | -16.66M |
| December 31, 2019 | -15.63M |
| September 30, 2019 | -11.51M |
| June 30, 2019 | -15.03M |
| March 31, 2019 | -14.94M |
| December 31, 2018 | -12.62M |
| September 30, 2018 | -10.55M |
| June 30, 2018 | -9.109M |
| March 31, 2018 | -9.604M |
| December 31, 2017 | -8.232M |
| September 30, 2017 | -5.443M |
| June 30, 2017 | -4.558M |
| March 31, 2017 | -4.03M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Legend Biotech Corp. | -20.87M |
| Ironwood Pharmaceuticals, Inc. | 58.28M |
| Verastem, Inc. | -43.91M |
| Fortress Biotech, Inc. | -59.28M |
| AbbVie, Inc. | 3.436B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -478.52M |
| Cash from Financing (Quarterly) | 10.38M |
| Free Cash Flow | -155.71M |
| Free Cash Flow Per Share (Quarterly) | -0.8774 |
| Free Cash Flow to Equity (Quarterly) | -49.08M |
| Free Cash Flow to Firm (Quarterly) | -49.16M |
| Free Cash Flow Yield | -3.09% |